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Background: The hallmark of Type 2 diabetes (T2D) is hyperglycemia, although there are multiple other metabolic
abnormalities that occur with T2D, including insulin resistance and dyslipidemia. To advance T2D prevention and
develop targeted therapies for its treatment, a greater understanding of the alterations in metabolic tissues
associated with T2D is necessary. The aim of this study was to use microarray analysis of gene expression in
metabolic tissues from a mouse model of pre-diabetes and T2D to further understand the metabolic abnormalities
that may contribute to T2D. We also aimed to uncover the novel genes and pathways regulated by the insulin
sensitizing agent (CL-316,243) to identify key pathways and target genes in metabolic tissues that can reverse the
diabetic phenotype.
Methods: Male MKR mice on an FVB/n background and age matched wild-type (WT) FVB/n mice were used in all
experiments. Skeletal muscle, liver and fat were isolated from prediabetic (3 week old) and diabetic (8 week old)
MKR mice. Male MKR mice were treated with CL-316,243. Skeletal muscle, liver and fat were isolated after the treatment
period. RNA was isolated from the metabolic tissues and subjected to microarray and KEGG database analysis.
Results: Significant decreases in the expression of mitochondrial and peroxisomal fatty acid oxidation genes were
found in the skeletal muscle and adipose tissue of adult MKR mice, and the liver of pre-diabetic MKR mice, compared
to WT controls. After treatment with CL-316,243, the circulating glucose and insulin concentrations in the MKR mice
improved, an increase in the expression of peroxisomal fatty acid oxidation genes was observed in addition to a
decrease in the expression of retinaldehyde dehydrogenases. These genes were not previously known to be regulated
by CL-316,243 treatment.
Conclusions: This study uncovers novel genes that may contribute to pharmacological reversal of insulin resistance
and T2D and may be targets for treatment. In addition, it explains the lower free fatty acid levels in MKR mice after
treatment with CL-316,243 and furthermore, it provides biomarker genes such as ACAA1 and HSD17b4 which could be
further probed in a future study.
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The global prevalence of diabetes is rising [1]. As a
result of population ageing, increasing rates of obesity
and a sedentary lifestyle, there is an increasing incidence
of Type 2 diabetes (T2D), which comprises 90% of dia-
betes cases worldwide [1,2]. There is an interplay* Correspondence: Emily.Gallagher@mssm.edu
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unless otherwise stated.between genetic susceptibility and environmental in-
fluences in this epidemic [3], and studies such as the
Diabetes Prevention Program (DPP) have demonstrated
that lifestyle intervention, particularly weight loss, leads
to a significant reduction in the risk of diabetes [4,5]. It
is generally believed that insulin resistance in metabolic
tissues (liver, fat, and skeletal muscle) is a key factor in
the development of T2D [6]. What causes the develop-
ment of insulin resistance in metabolic tissues is unclear.
However, reducing insulin resistance by using medications,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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diabetes [5,7]. Beta-3 agonists improve insulin resistance in
animals, and short-term human studies, with evidence of
browning of white adipose tissue in rodent studies [8,9];
but the mechanisms through which this occurs are incom-
pletely understood.
Inter-tissue cross talk between skeletal muscle, adipose
tissue, the liver, brain, and pancreatic beta cells may con-
tribute to insulin resistance. Increasing circulating levels
of free fatty acids (FFAs) and triglycerides (TG) from
adipose tissue lipolysis are frequently observed in pre-
diabetes and T2D and contribute to insulin resistance.
Abnormalities in fatty acid metabolism contribute to the
accumulation of lipids in tissues such as skeletal muscle
and liver and to the development or worsening of insulin
resistance [10]. Other molecules, such as myokines and
adipokines may contribute to inter-tissue cross talk.
Skeletal muscle, for example releases a number of myo-
kines that can act in an autocrine, paracrine, or endo-
crine manner to regulate metabolic processes [11,12].
Adipose tissue releases multiple adipokines, including
leptin, adiponectin and resistin that act through their re-
ceptors on many other organs to regulate metabolism.
In this study we have used an animal model of insulin
resistance and T2D to understand the gene expression
changes that occur in pre-diabetes, T2D, and pharmaco-
logical treatment of T2D. The LeRoith lab developed a
transgenic mouse model of T2D that overexpresses a
dominant-negative IGF-1R (KR-IGF-1R) specifically in
the skeletal muscle under the muscle creatine kinase
(MCK) promoter [13]. The male MKR mice exhibit
hyperinsulinemia by 2–3 weeks of age, and hypergly-
cemia by 5–6 weeks of age with decreased whole body
glucose uptake, failure to suppress hepatic gluconeogen-
esis in response to insulin and pancreatic beta cell
dysfunction [13,14]. In addition, the male MKR mice
have elevated circulating free fatty acids, triglycerides,
and hepatic and muscle triglyceride content, compared
to wild-type mice [13,15]. We chose the MKR mouse
for these studies as this mouse model has a well-
characterized progression from “pre-diabetes” to overt
diabetes with hyperglycemia, without the need for high
fat diet feeding. Therefore, this allows us to study the
effects of insulin resistance in different tissues without the
confounding effects of different diets with different fat
contents. Therefore, the male MKR mouse is an excellent
mouse model for studying the metabolic derangements
associated with the pre-diabetic insulin resistant state and
the diabetic hyperglycemic condition.
Previous gene expression studies on T2D have focused
on single metabolic tissues [16-22], have studied target
genes or proteins [13,23-27], or have been performed
in vitro in cell culture studies [28-31]. None of these
studies have explored the global gene expression changesin multiple tissues, or those caused by the administra-
tion of the insulin sensitizing beta-3 adrenergic agonist
(CL–316, 243). In this study, we aimed to uncover novel
changes in metabolic tissues (skeletal muscle, liver and
adipose tissue) between pre-diabetic and diabetic MKR
mice, using microarrays and the Kyoto Encyclopedia
of Genes and Genomes (KEGG) database analyses. The
KEGG database is a comprehensive database constructed
from well-known molecular interaction networks and is
extensively used to study biological pathways [32]. The
enrichment of KEGG pathways was used to encode all
significantly differentially expressed genes in this study.
The study of extracted KEGG pathways related to T2D,
indicate that they may help building effective computa-
tional tools in the study of T2D. In addition to examining
differences in the metabolic tissues in the pre-diabetic
and diabetic models, we also aimed to uncover novel
genes and pathways that were altered by the pharma-
cological treatment with a CL-316,243 [26]. Using the
same methods, we uncovered novel genes and pathways




All animal studies were approved by the Mount Sinai
School of Medicine Institutional Animal Care and Use
Committee. Mice were housed in The Mount Sinai
School of Medicine Center for Comparative Medicine
and Surgery, Association for Assessment and Accreditation
of Laboratory Animal Care International (AALAC) and
Office of Laboratory Animal Welfare (OLAW) accredited
facility, where animal care and maintenance were provided.
Mice were kept on a 12 hour light/dark cycle, had free
access to diet (Picolab Rodent Diet 20, 5053) and fresh
water. All MKR and WT mice used in these studies were
male, on the FVB/N background and were 3–12 weeks of
age. The generation and characterization of the MKR mice
have been previously described [13]. All tissues were col-
lected from mice in the fed state. Three animals per group
were used in each microarray experiment. Liver, gonadal
fat and skeletal muscle (quadriceps) were collected
and flash frozen in liquid nitrogen for subsequent RNA
extraction.
Treatment with CL-316,243
We have previously demonstrated that the beta-3 agon-
ist CL-316,243 improves insulin sensitivity and lowers
glucose levels in the MKR mice [26,33]. Nine to ten
week old male WT and MKR mice were injected intra-
peritoneally with CL-316,243 (1 mg/kg BW/day) or with
an equivalent volume of vehicle (sterile water and phos-
phate buffered saline) for three weeks, n = 5-8 per group.
Body weight was measured before treatment and twice
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performed using the EchoMRI 3-in-1 NMR system
(Echo Medical Systems, Houston, TX, USA) before treat-
ment, and 13 days after the start of treatment. Fed blood
glucose measurements were performed on tail vein
blood during tumor studies using a Bayer Contour Gluc-
ometer (Bayer Healthcare, Mishawaka, IN, USA), prior
to commencing treatment and weekly thereafter. Plasma
fed insulin levels were measured at the end of the stud-
ies using the Sensitive Rat Insulin RIA kit (Millipore, St.
Charles, MO, USA). Serum triglycerides were mea-
sured using the Point Scientific Liquid Reagent (Pointe
Scientific, Canton, MI, USA). Means for each group and
standard error of the means were calculated. Differences
between groups were analyzed by a One-Way ANOVA
Test with a Tukey-Kramer Post-Hoc Test, assuming a sig-
nificance level of 5% using SigmaStat 3.5 (Systat Software
Inc, San Jose, CA, USA).
RNA isolation and microarray analysis procedures
Total RNA was isolated from the liver, fat, and skel-
etal muscle tissues of three mice from each group
using the RNeasy Microarray Tissue Mini kit (Qiagen,
Valencia, CA, USA), according to the manufacturer’s
instructions. The concentration and quality of RNA was
determined using the NanoDrop 2000 Spectrophotometer
(Thermo Scientific, Wilmington, DE, USA), the Agilent
2100 Bioanalyzer (Agilent, Santa Clara, CA, USA), and
RNA Integrity Number (RIN, Agilent, Santa Clara,
CA, USA). All samples used for reverse transcription
and microarray analysis had 260/280 ratios greater
than 1.8 on the Nanodrop Spectrophotometer and
RIN values greater than 8.0. 100 ng of RNA from
each sample was reverse transcribed to cDNA and
amplified using NUGEN Applause WT–Amp ST sys-
tem (NuGEN Technologies, San Carlos, CA, USA),
according to the manufacturer’s protocol. 2.5 μg of
cDNA was fragmented and 3′-biotinylated using Encore
Biotin Module (NuGEN Technologies, San Carlos, CA,
USA). The resultant sample mix with hybridization re-
agents were loaded into the GeneChip Mouse Gene 1.0
ST array and incubated for 16–20 hours in hybridization
oven rotating at 60 rpm at 45°C (Affymetrix, Santa Clara,
CA, USA). Arrays were processed using GeneChip
Fluidics Station 450 (Affymetrix, Santa Clara, CA,
USA). Chips were scanned using the GeneChip Scanner
3000 (Affymetrix, Santa Clara, CA, USA), operated by
Gene Chip Operating Software, version 1. 4 and generated
.CEL, .CHP and RPT files. Poly-A controls (dap, lys, phe,
thr) and hybridization controls (bioB, bioC, bioD and cre)
were used as spike controls for cDNA synthesis and
hybridization, respectively, using methods described in
the manufacturer’s instructions (Affymetrix, Santa Clara,
CA, USA).The microarray raw data was analyzed using Partek
software, version 6.3 (Partek. St. Louis, MO, USA). Raw
data was subjected to Robust Multichip Average (RMA)
quantile normalization to remove biases introduced by
technical and experimental effects. All expression data
were log base 2 -transformed to get near normal distri-
bution for accurate statistical inference. Quality control
by visualizing the data using Principal Component Ana-
lysis cluster plot ensured that no outliers were included
for the analysis. Next, two-way ANOVA analysis was
performed to obtain a set of differentially expressed
genes. A filter of p value < 0.05 and fold-change > 1.5 times
was applied to identify the significantly differentially
expressed genes.
The significantly differentially expressed genes list was
exported to Ingenuity Pathway Analysis (Ingenuity Systems,
Redwood City, CA) for finding biological inference. Statisti-
cally significant genes from Partek analysis were overlaid
on the Ingenuity Pathway Analysis (IPA) global molecular
network after applying a filter on species (mouse) and
tissue type.
KEGG pathways analysis
Kyoto Encyclopedia of Genes and Genomes (KEGG)
database pathways and their corresponding genes were
downloaded from KEGG website (http://www.genome.jp/
kegg/) on 11 June 2014 [34,35]. Differentially expressed
genes for each study type, i.e. MKR vs WT (fat, skeletal
muscle, and liver tissues) and CL 316,243 treated MKR vs
vehicle treated MKR fat tissues and genes from entire
mouse genome were mapped to each KEGG pathway.
This provided a list of count of genes in each of the above
four datasets and the entire mouse genome annotated to
each KEGG pathway. Calculation of enrichment P values
is based on the following mathematical approach: in a
dataset of N genes from entire genome, where M genes
are annotated to a particular KEGG pathway, and n genes
are differentially expressed, then the probability of having
k genes to be differentially expressed and also included in
the above KEGG pathway is given by a hypergeometric













Based on this approach, calculations of enrichment P
values and programming tasks were performed using
MATLAB version 2010a [Natick, Massachusetts: The
MathWorks Inc., 2010]. Enrichment P values were cal-
culated using MATLAB’s hygecdf and hygepdf functions.
The enrichment P value cutoff for KEGG analysis was
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ing of multiple pathways.
Results
KEGG pathways analysis of the microarray results
The results of the microarray analysis are summarized in
Venn diagrams shown in Figure 1a and 1b. KEGG path-
ways analysis was done to determine overrepresented
pathways (containing high number of differentially ex-
pressed genes). The results of KEGG pathway analysis of
lipid metabolism is shown in Table 1. The following
pathways were found to be significantly overrepresented
in fat tissues of MKR vs WT mice: fatty acid degradation,
glycerolipid metabolism, and glycerophospholipid metab-
olism. When fat tissues of CL-316,243 treated MKR mice
were compared with non-treated MKR mice, the glyce-
rolipid metabolism, glycerophospholipid metabolism, fat
digestion and absorption, and ether lipid metabolism
were found to be significantly overrepresented. Circu-
lating ether lipid levels have previously found to be sig-
nificantly higher in obese and diabetic subjects [37]. As
shown in Figure 1c when fat tissues of treated MKR were
compared with non-treated MKR difference in dysregula-
tion of ether lipid metabolism was observed. Most of the
genes in fat tissues related to ether lipid metabolism were
found to be down-regulated in MKR compared with WT
mice. Following treatment this trend was reversed. A
complete list of KEGG enrichment analysis results isFigure 1 Results from differential change analyses. a) Venn diagram sh
change between different datasets. b) Venn diagram showing overlap of sign
treated (Treated) vs untreated MKR (MKR) fat and untreated MKR vs WT fat tis
corresponding to the color scheme in Venn diagram. Other colors correspondprovided in Additional file 1: Table S1. In addition, path-
ways related to carbohydrate metabolism such as TCA
cycle, pentose phosphate pathway, fructose and mannose
metabolism, pyruvate metabolism, and propanoate metab-
olism were found to be overrepresented only in fat tissues
of MKR vs WT mice and not in the fat tissues of CL-
316,243 treated MKR compared with non-treated MKR.
Moreover, carbohydrate metabolism pathway amino
sugar and nucleotide sugar metabolism was found to be
overrepresented only after treatment with CL-316,243 in
fat tissues of MKR mice.
Fatty acid oxidation genes are dysregulated in the adipose
tissues of the diabetic MKR mice compared with WT mice
Although the diabetic MKR mice were generated by
overexpression of a dominant-negative human IGF-1R
in skeletal muscle, it has previously been found that
these mice also develop insulin resistance in liver and
adipose tissue as well as a decrease in adipose tissue
mass. Pathway analysis of the gene expression in the
adipose tissue of MKR and WT mice by microarrays re-
vealed dysregulated expression of the TCA cycle, branched
chain amino acid (valine) degradation, tryptophan deg-
radation, N-glycan biosynthesis, pyrimidine metabolism,
ether lipid metabolism, and fatty acid oxidation. As the
MKR mice have been previously found to have changes
in fatty acid metabolism in the skeletal muscle, with
increased adipose tissue and hepatic insulin resistance,owing significant genes (<0.05 P value) with 1.5X differential fold
ificant genes with more than 1.5X fold change difference in CL-316,243
sues datasets c) Ether lipid metabolism KEGG pathway – color scheme is
to genes found in mouse genome but not in either datasets.
Table 1 Kegg pathways enrichment P values in the differentially expressed gene sets
Pathway name P value MKR vs
WT fat
P value MKR vs
WT liver
P value MKR vs WT
skeletal muscle
P value prediabetic
MKR vs WT liver
P value CL treated MKR vs
vehicle-treated MKR fat
Fatty acid biosynthesis 0.037 0.006 0.259 0.007 0.676
Fatty acid elongation 0.026 0.201 0.016 1.61E-05 0.731
Fatty acid degradation 1.79E-08 0.319 1.17E-05 3.31E-14 0.012
Synthesis and degradation
of ketone bodies
0.381 0.422 0.103 5.27E-05 0.183
Steroid biosynthesis 0.060 0.081 0.002 9.23E-08 0.166
Primary bile acid biosynthesis 0.081 0.036 0.027 0.001 0.073
Steroid hormone biosynthesis 0.341 0.0008 0.097 0.001 0.114
Glycerolipid metabolism 8.45E-06 2.90E-05 1.98E-08 2.84E-08 7.49E-06
Fat digestion and absorption 0.181 0.244 5.40E-03 2.57E-05 6.86E-03
Glycerophospholipid metabolism 3.27E-12 9.99E-06 5.75E-08 2.22E-08 7.57E-09
Ether lipid metabolism 0.0004 0.002 0.002 0.0006 5.61E-07
Sphingolipid metabolism 0.079 0.0003 0.007 0.002 0.0003
Arachidonic acid metabolism 0.014 0.001 0.002 0.007 0.002
Linoleic acid metabolism 0.054 0.248 0.025 0.065 0.010
alpha-Linolenic acid metabolism 0.012 0.050 0.055 0.015 0.001
Biosynthesis of unsaturated
fatty acids
0.085 0.006 0.055 3.35E-06 0.153
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expression of genes in the fatty acid oxidation path-
way in the adipose tissue of the MKR mice, compared
to WT mice. We found down regulation of number
of genes involved in fatty acid oxidation in adiposeFigure 2 Gene network analysis of the fatty acid oxidation pathway i
down-regulation, red represents up-regulation, white symbols denote neighb
in the tissue from the MKR mice vs WT mice. The numbers below the symbotissue (Figure 2, Table 2), with a few notable exceptions,
including the aldehyde dehydrogenases ALDH3A2 and
ALDH7A1, the acyl CoA synthetases ACSL4 and ACSBG2
and the peroxisomal fatty acid oxidase ACOX3, that were
upregulated in the adipose tissue of the MKR mice.n adipose tissue from MKR vs WT mice. Green represents
oring genes. The intensity of color represents the average of fold changes
ls denote the fold change in gene expression of MKR vs WT mice.
Table 2 Gene expression data for fatty acid oxidation pathway genes in adipose tissue from MKR vs WT mice
Gene name MKR vs WT Gene name MKR vs WT Gene name MKR vs WT
CYP2E1 −2.7887 HADHA −1.9032 CPT1A NA
ACADVL −2.64 HADHB −1.8385 ALDH2 NA
HSD17B8 −2.428 ECHS1 −1.8378 SLC27A6 NA
ADHFE1 −2.3643 SLC27A4 −1.7369 SDS NA
ACSBG1 −2.3277 ACSL6 −1.736 ACAT1 NA
HSD17B4 −2.3023 ACADL −1.6304 ADH6A NA
ACAA1 −2.2625 ACSL5 −1.6065 ADH5 NA
ACOX1 −2.175 SLC27A1 −1.572 DCXR NA
ACSL1 −2.174 ACOX3 1.54147 ALDH1A2 NA
ACADM −2.1376 ACSBG2 1.60749 ALDH1A1 NA
CPT2 −2.1299 ALDH7A1 1.78087 SLC27A5 NA
HSD17B10 −2.1022 ALDH3A2 1.8053 IVD NA
EHHADH −2.0911 ACSL4 3.1309 CPT1A NA
NA corresponds to that gene expression data was not available in the cut-off dataset (Fold-change > 1.5X and p-value < 0.05).
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oxidation genes in the skeletal muscle of MKR mice
We next examined the expression of fatty acid oxidation
genes in the skeletal muscle of the MKR and WT mice
by microarray analysis. Significant differences were found
in the fatty acid oxidation pathway between MKR and
WT mice. The MKR mice had a significant downre-
gulation of many of the genes involved in fatty acid beta-
oxidation (Figure 3, Table 3). Notable exceptions to the
general downregulation of fatty acid oxidation genes inFigure 3 Gene network analysis of the fatty acid oxidation pathway i
down-regulation, red represents up-regulation, white symbols denote neighb
in the tissue from the MKR mice vs WT mice. The numbers below the symbothe skeletal muscle of the MKR mice include carnitine
palmitoyl transferase 1a (CPT1A), the peroxisomal acyl
CoA oxidase ACOX3, the alcohol dehydrogenase ADH6A,
dicarbonyl/L-xylulose reductase DCXR, and the aldehyde/
retinaldehyde dehydrogenase ALDH1A2, which were
upregulated approximately 2 fold (Table 3). ACOX3
was upregulated in both the adipose tissue and the
skeletal muscle of the MKR mice. It is one of the three
acyl CoA oxidases that perform the first step of fatty acid
oxidation in mouse peroxisomes, specifically the oxidationn skeletal muscle from MKR vs WT mice. Green represents
oring genes. The intensity of color represents the average of fold changes
ls denote the fold change in gene expression of MKR vs WT mice.
Table 3 Gene expression data for fatty acid oxidation pathway genes in skeletal muscle from MKR vs WT mice
Gene name MKR vs WT Gene name MKR vs WT Gene name MKR vs WT
ALDH1A1 −4.19187 ACADVL −1.7823 ACSBG1 NA
HSD17B4 −3.58868 CPT2 −1.73571 ACSL5 NA
ACAA1 −3.11098 ALDH2 −1.73348 SLC27A1 NA
ACSL3 −2.40998 HSD17B10 −1.67733 ACSL1 NA
IVD −2.25629 ACSBG2 −1.60441 EHHADH NA
ACOX1 −2.14926 CYP2E1 −1.56151 HADHB NA
ACSL4 −2.12389 HADHA −1.54366 SDS NA
ACSL6 −2.10271 ADH5 −1.54339 ACADM NA
ECHS1 −2.02957 ALDH1A2 1.72927 ACADL NA
ALDH3A2 −1.97016 CPT1A 1.95779 ALDH7A1 NA
SLC27A4 −1.95574 DCXR 2.01625 ADHFE1 NA
ACAA2 −1.82191 ACOX3 2.02906
ACAT1 −1.78422 ADH6A 2.19604
NA corresponds to that gene expression data was not available in the cut-off dataset (Fold-change > 1.5X and p-value < 0.05).
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downregulated in the skeletal muscle and adipose tissue of
MKR mice, metabolizes very long-chain fatty acids and
long-chain dicarboxylic acids (DCAs). The primary gen-
etic defect in the MKR mice is in the skeletal muscle,
and the muscle of the MKR mice have been previously
shown to have greater accumulation of fatty acid inter-
mediates compared to WT mice. Therefore, the results
of our microarray analysis on the skeletal muscle were
consistent with our previously published data showing a
decrease in fatty acid oxidation; although the microarray
data demonstrated previously unidentified novel changesFigure 4 Gene network analysis of the fatty acid oxidation pathway i
represents up-regulation, white symbols denote neighboring genes. The in
from the MKR mice vs WT mice. The numbers below the symbols denote tin gene expression in this pathway in the skeletal muscle
of the MKR mice.
No changes in hepatic fatty acid oxidation gene
expression were found in the liver of adult diabetic MKR
mice
The liver in the MKR mice is known to have increased
triglyceride deposits compared to WT mice [13], and
demonstrate hepatic insulin resistance with failure to
suppress gluconeogenesis [13]. Therefore, we hypothe-
sized that we would also find a downregulation of fatty
acid oxidation genes in the liver of the MKR mice.n liver from MKR vs WT mice. Green represents down-regulation, red
tensity of color represents the average of fold changes in the tissue
he fold change in gene expression of MKR vs WT mice.
Table 4 Gene expression data for fatty acid oxidation pathway genes in liver from MKR vs WT mice
Gene name MKR vs WT Gene name MKR vs WT Gene name MKR vs WT
SDS −3.28557 CPT1A NA ADH6A NA
ACSBG1 −1.72659 CPT2 NA ADH5 NA
ALDH3A2 1.55345 ACOX1 NA ACADM NA
ACSBG2 1.74991 ACOX3 NA ACADL NA
ALDH1A2 1.90081 ACADVL NA ALDH2 NA
ACSL6 2.4039 EHHADH NA ALDH7A1 NA
ACAA1 2.47745 ECHS1 NA DCXR NA
ACSL4 2.94002 HADHA NA ADHFE1 NA
ACSL5 NA HADHB NA ALDH1A1 NA
SLC27A1 NA HSD17B10 NA CYP2E1 NA
SLC27A4 NA HSD17B4 NA
ACSL1 NA ACAT1 NA
NA corresponds to that gene expression data was not available in the cut-off dataset (Fold-change > 1.5X and p-value < 0.05).
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no significant changes in fatty acid oxidation genes in
the adult MKR mouse, compared to WT mice
(Figure 4, Table 4). Decreased expression of only two
genes in this pathway, the acyl CoA synthetase
ACSBG1 and serine dehydratase (SDS) was found,
while notably, an increase in acetyl CoA acyltransfer-
ase 1 (ACAA1) and the acyl CoA synthetase, ACSL6
was found (both of which had decreased expression
in the skeletal muscle and adipose tissue of MKR
mice). Therefore, despite the insulin resistance in the
liver of the MKR mice and known hepatic TG accu-
mulation, no significant decrease in the genes of hep-
atic FA oxidation found.Table 5 Gene expression data for fatty acid oxidation pathwa
WT mice














NA corresponds to that gene expression data was not available in the cut-off datas
MKR mice).Hepatic fatty acid oxidation genes were significantly
downregulated in the pre-diabetic MKR mouse
We then examined the gene expression of the liver from
3-week-old pre-diabetic MKR mice to age-matched WT
mice. The 3-week old MKR mice have insulin resistance
and hyperinsulinemia, but are not hyperglycemic, and are
therefore a model of pre-diabetes. Our previous studies
have demonstrated that the MKR mice at 3 weeks of
age have significant increases in hepatic triglyceride
content when compared to WT mice [13]. Using the
same methods, our microarray analysis revealed that
the FA oxidation pathway was the most significantly
dysregulated pathway in the liver of the pre-diabetic
MKR mice with significant and substantial decreasesy genes in liver from pre-diabetic MKR vs age-matched














et (Fold-change > 1.5X and p-value < 0.05). PD denotes prediabetic (3 week old
Table 6 Metabolic parameters from WT and MKR mice at baseline, and after 2 weeks of treatment with CL-316,243 tor
vehicle
WT vehicle WT CL-316,243 MKR vehicle MKR CL-316,243
Baseline 2 weeks Baseline 2 weeks Baseline 2 weeks Baseline 2 weeks
Body weight (g) 27.95 (0.93) 28.47 (1.13) 28.03 (0.48) 27.15 (0.55) 23.97 (1.07)a 24.19 (0.63) 22.15 (0.59) 22.16 (0.23)
Blood glucose (mg/dL) 146.43 (2.89) 157.29 (6.71) 152.75 (5.55) 184.88 (10.28) 387.60 (52.33)a 380.80 (24.37) 335.40 (36.10) 226.20 (16.23)b
Body fat (%) 14.02 (1.26) 12.83 (1.36) 12.58 (0.92) 6.41 (0.51)c 11.28 (0.71) 11.00 (1.07) 12.45 (0.77) 4.46 (0.40)b
Serum TG (mmol/L) 2.29 (0.06) 1.62 (0.03)d 4.90 (0.10)e 3.77 (0.04)f
Plasma insulin (ng/ml) 1.50 (0.97) 0.82 (0.51) 8.58 (3.85)e 0.80 (0.28)f
Metabolic parameters from wild type (WT) and MKR mice at baseline and after 2 weeks of treatment with CL-316,243. Data in table are means of each group and
SEM in parenthesis. One Way ANOVA analysis and Tukey-Kramer post-hoc significance test was performed, assuming a significance level of 5%. The following
differences in the group means were found: aMKR Vehicle Baseline vs WT Vehicle Baseline; bMKR CL-316,243 2 weeks vs MKR CL-316,243 Baseline; cWT
CL-316,243 2 weeks vs WT CL-316,243 Baseline; dWT CL-316,243 2 weeks vs WT Vehicle 2 weeks; eMKR Vehicle 2 weeks vs WT Vehicle 2 weeks; fMKR CL-316,243 2 weeks
vs MKR Vehicle 2 weeks.
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compared to the age-matched control mice (Table 5).
Treatment of adult MKR mice with the beta 3-adrenergic
receptor agonist CL-316,243 led to improvement in
metabolic parameters and altered expression of fatty acid
oxidation genes
WT and MKR mice were treated for two weeks with CL-
316,243. Consistent with our previous studies, a decrease
in random fed blood glucose, fed plasma insulin, serum
triglyceride concentration and body fat was observed in
the MKR mice after two weeks of treatment (Table 6).
Microarray analysis of adipose tissue from MKR miceFigure 5 Gene network analysis of the fatty acid oxidation pathway i
mice. Green represents down-regulation, red represents up-regulation, wh
represents the average of fold changes in the tissue from the MKR CL-316,2
the symbols denote the fold change in gene expression of MKR CL-316,243treated with CL-316,243 revealed a significant change in
the expression of a number of the genes in the FA oxida-
tion pathway that were differentially regulated in the
MKR compared to WT mice (Figure 5, Table 7). Genes
that were downregulated in the MKR adipose tissue, but
then were upregulated after CL-316,243 treatment in-
cluded acyl CoA acyltransferase (ACAA1), the acyl CoA
synthetase ACSL6, the alcohol dehydrogenase ADHFE1,
and the hydroxysteroid dehydrogenase HSD17B4. Genes
that were upregulated in the adipose tissue of MKR mice
compared to WT mice and were downregulated after
CL-316,343 treatment included the peroxisomal fatty
acid oxidation enzyme ACOX3, and the aldehyden adipose tissue from CL-316,243 MKR vs vehicle-treated MKR
ite symbols denote neighboring genes. The intensity of color
43 treated MKR mice vs vehicle treated MKR mice. The numbers below
treated vs vehicle treated mice.
Table 7 Gene expression data for fatty acid oxidation pathway genes in adipose from CL-316,243 treated MKR vs vehicle
treated MKR mice
Gene name TR vs MKR Gene name TR vs MKR Gene name TR vs MKR
ALDH1A2 −5.1818 DCXR −1.6946 SLC27A1 NA
ALDH1A1 −4.1157 ACSL1 −1.5251 ACSL4 NA
SLC27A4 −3.8033 ADHFE1 1.52237 CPT2 NA
ALDH2 −3.7982 HSD17B4 1.54675 ACADM NA
CPT1A −3.6059 SLC27A6 1.60681 ACADL NA
ACSL5 −3.0073 ACAT1 1.89588 HSD17B8 NA
ACOX3 −2.7208 ACSBG2 1.89683 ACADVL NA
ALDH7A1 −2.5909 ADH6A 2.02657 EHHADH NA
ALDH3A2 −2.3444 ACAA1 2.02752 ECHS1 NA
IVD −2.2947 ACSL6 2.10495 HADHA NA
ACOX1 −2.0718 SLC27A5 2.51732 HADHB NA
ADH5 −1.9237 SDS 2.65876 HSD17B10 NA
CYP2E1 −1.7096 ACSBG1 NA
NA corresponds to that gene expression data was not available in the cut-off dataset (Fold-change > 1.5X and p-value < 0.05). TR denotes CL-316,243 treated MKR
mice, MKR denotes vehicle treated MKR mice.
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316,243 treatment led to a significant downregulation of
retinaldehyde dehydrogenases, including ALDH1A1 in
the adipose tissue of MKR mice, the deficiency of which
has previously been associated with browning of adipose
tissue, a phenomenon observed with CL-316,243 treat-
ment [46]. As shown in Table 7, a number of genes in
the FA oxidation pathway were altered by CL-316,243
treatment but were not differentially regulated between
the WT and MKR mice, and many genes were further
downregulated by CL-316,243 treatment. These genes
may be downregulated after chronic administration of
CL-316,243, but may be increased in the acute setting,
or their altered expression may be related to the brown-
ing of white adipose tissue observed after CL-316,243
treatment.
Discussion
The key finding in this study is the significant down-
regulation of FA oxidation genes in the skeletal muscle
and adipose tissues of MKR mouse model of Type 2
diabetes, and in the pre-diabetic insulin resistant liver of
these mice. The finding shows dysregulation of FA oxi-
dation in the tested tissues of the insulin resistant, pre-
diabetic and diabetic state and altered expression in
genes that regulate peroxisomal beta-oxidation of fatty
acids. Treatment of the mice with a beta-3 adrenergic
receptor agonist improved the diabetic state and led to
the differential regulation of genes involved in peroxi-
somal fatty acid oxidation and genes that have been previ-
ously reported to regulate browning of white adipose
tissue in genetic knockout mice, but have not been previ-
ously shown to be regulated by a pharmacological agentsuch as the one used in this study. This robust study on
changes in gene expressions after treatment with beta 3-
adrenergic receptor agonist, highlights novel findings for
better understanding of pathophysiology of T2D in MKR
mice, and identifies potential treatment targets.
Computational efforts to understand diseases, such as
T2D, with enormous complexity affecting more than one
organ, have accelerated the understanding of the per-
turbed metabolism in such pathophysiological conditions.
We have previously utilized computational approaches to
develop a multi-confidence level multi-tissue model to
study T2D [47]. To understand the mechanism of CL
316,243 compound on diabetic mice, a thorough compu-
tational analysis was performed using KEGG pathways
analysis based on hypergeometric test and Ingenuity
Pathway Analysis (IPA – www.ingenuity.com) based on
Fisher’s exact test. The results revealed that treatment with
CL-316,243 led to dysregulation of ether lipid metabolism
as well as pathways such as fat digestion and absorption,
glycerolipid metabolism, and glycerophospholipid metabol-
ism. Additionally, the TCA cycle that was highly overrepre-
sented in MKR fat tissues was back to the same level as the
healthy animals following CL-316,243 treatment. In short,
the overrepresentation of TCA cycle during T2D was
found to be reversed after treatment with the drug.
Defects in fatty acid oxidation may cause the accrual
of fatty acyl CoAs and diacylglycerol in the skeletal
muscle of obese subjects, resulting in inhibition of insulin-
mediated glucose uptake and insulin resistance [48,49]. In
the setting of hyperinsulinemia in insulin-treated rodents,
hepatic expression of sterol regulatory binding protein 1c
(SREBP-1c) increased, along with increased expression of
acetyl CoA carboxylase (ACC) and other lipogenic
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in the liver [50]. Individuals with T2D have increased
adipose tissue lipolysis that leads to increased circu-
lating free fatty acids [51]. In a study of 72 human
subjects who underwent insulin clamp studies, skel-
etal muscle and adipose tissue biopsies, impaired fatty
acid and branched chain amino acid metabolism were
proportional to the degree of insulin resistance [52].
While initial reports stated that white adipose tissue
is not an important tissue for fatty acid oxidation
[53], later studies have shown that although the rate
of fatty acid oxidation is low in white adipose tissue,
normal fatty acid oxidation in adipocytes is important
to regulate circulating free fatty acid concentrations
and to prevent the development of fatty liver and
beta cell dysfunction [54].
Previous genome wide association studies have identi-
fied subsets of gene candidates for T2D [55]. Of the
genes identified in that study, some were involved in the
metabolism of fatty acids and amino acids, and were also
found in our present study to be differentially regulated
in the skeletal muscle (ACAA2, ECHS1), and adipose
tissue (ECHS1) of the adult MKR mice, and in the liver
of pre-diabetic MKR mice (ACAA2, ECHS1). ACAA2
encodes the protein acetyl CoA acyltransferase 2 that
catalyzes the final step of mitochondrial fatty acid oxi-
dation along with acetyl coA thiolase (ACAT1), which is
also downregulated in the skeletal muscle of adult MKR
mice, and in the liver of pre-diabetic mice. ECHS1 en-
codes enoyl CoA hydratase short chain 1 and catalyzes
the second step of mitochondrial FA oxidation.
Beta-oxidation of fatty acids occurs in the peroxisomes
and the mitochondria. The mitochondria oxidize the ma-
jority of long chain fatty acids (LCFAs) from diet and fat
stores, while the peroxisomes oxidize specific carboxylic
acids, including very long-chain fatty acids (VLCFAs),
branched-chain fatty acids (BCFAs), bile acids and fatty di-
carboxylic acids. Mouse peroxisomes have three acyl CoA
oxidases that perform the first step of beta-oxidation.
ACOX1 the first step oxidizes the straight chain substrates
such as very long-chain fatty acids and long-chain dicar-
boxylic acids (DCAs), ACOX2 is active with the bile acid
intermediates and the branched-chain fatty acids and
ACOX3 accepts the branched-chain fatty acids [38-45].
The second and third steps of peroxisomal beta-
oxidation involve Hsd17b4 (also known as D-peroxisomal
bifunctional enzyme) and EHHADH (also known as
L-peroxisomal bifunctional enzyme). The peroxisomal
beta-oxidation genes that are differentially regulated
in the tissues of the MKR mice are the fatty acid
transporter SLC27A1 (also known as FATP1 or ACSVL4)
in adipose tissue, and SLC27A4 (FATP4, ACSVL5) in
adipose tissue, skeletal muscle and pre-diabetic liver.
In human studies, links between both SLC27A1 andSLC27A4, and obesity and T2D have been proposed
[56,57]. SLC27A1 overexpression in primary human
myocytes and HEK293 cells has been reported to trig-
ger increased incorporation of FAs into triacylglycerol,
and an increase in 1,2-diacylglycerol acyltransferase
activity [58,59]. Reduced triacylglycerol deposition has
been observed in 3 T3-L1 adipocytes with shRNA- in-
duced knockdown of SLC27A1 [60]. Insulin has been
shown to have varying effects on SLC27A1 expression in
adipocytes, with an early repression, followed by a stimu-
lation during differentiation and a subsequent repression
in mature adipocytes [61]. Insulin may also stimulate the
translocation of SLC27A1 to the cell surface in adipo-
cytes, however SLC27A4 is not recruited to the plasma
membrane by insulin [62,63]. Of all the FA oxidation
genes found to have lower expression in the pre-diabetic
MKR mouse liver, EHHADH expression decreased more
than seven fold compared with the WT mice. Adult MKR
adipose tissue, skeletal muscle, and the liver of prediabetic
MKR mice also showed significant decrease in the expres-
sion of HSD17b4 which appears to be able to handle all of
the peroxisomal beta oxidation substrates [44]. Recent
studies have shown that L-PBE is protective against the
over-accumulation of DCAs in mice fed MCFAs in the
form of coconut oil [64]. L-PBE knockout mice fed with
diet high in MCFAs developed DCA accumulation in the
liver, inflammation, hepatic fibrosis and death [64].
HSD17b4 deficient patients and Hsd17b4 knockout mice
accumulate VLCFAs, BCFAs and bile acid intermediates
[65,66]. Our microarray analysis thus demonstrates signifi-
cant differences in peroxisomal FA oxidation genes be-
tween the MKR and WT mice in different tissues that
may indicate that abnormalities in peroxisomal beta-
oxidation, contribute to the accumulation of DCAs and
play a role in the development of insulin resistance.
The relative lack of difference in fatty acid oxidation
gene expression in the liver of adult MKR compared
with WT mice was an unexpected finding, as the MKR
mice have increased hepatic TG content compared to
WT mice [23]. In addition, the FA oxidation pathway
was the most significantly down-regulated pathway in
the pre-diabetic MKR mice. Possible explanations for the
normalization of FA oxidation in the adult MKR mouse
are that the described abnormalities in peroxisomal FA
oxidation may lead to accumulation of DCAs. DCAs
induce PPARα FA oxidation genes [64], and therefore the
accumulation of DCAs in the pre-diabetic liver which may
lead to an up-regulation (or normalization) of FA oxida-
tion genes in the adult mice. Alternatively, if FA oxidation
is impaired, then gluconeogenesis will not occur and fast-
ing hypoglycemia will result. Therefore, the lack of down-
regulated fatty acid oxidation in the adult MKR mice may
provide the fuel for gluconeogenesis and the maintenance
of hyperglycemia [67]. This hypothesis is supported by the
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ACSL4 as well as acetyl CoA acyltransferase 1 (ACAA1)
and the retinaldehyde dehydrogenase 2 (ALDH1A2), which
may be involved in hepatic gluconeogenesis [68].
Treatment with CL-316,243 showed enrichment of
many biochemical pathways and an increase in the expres-
sion of the peroxisomal FA oxidation enzymes ACAA1
and HSD17b4 in adipose tissue of MKR mice. It is
interesting that, chronic CL-316,243 treatment led to
a significant down-regulation of several retinaldehyde
dehydrogenases, including ALDH1A1 in the white adipose
tissue of MKR mice. Aldehyde dehydrogenases convert
retinaldehyde to retinoic acid. ALDH1A1 deficiency in-
duces a brown adipose tissue-like transcriptional program
in white adipose tissue, with uncoupling of respiration and
adaptive thermogenesis [68]. In obese mice, ALDH1A1
knockdown led to a reduction in weight gain and im-
provement in glucose homeostasis [68]. No previous stud-
ies have demonstrated that beta 3 adrenergic receptor
agonists decrease the expression of aldehyde dehydroge-
nases and the function of the Aldh family of enzymes is
still being elucidated [69,70]. These changes may contrib-
ute to the systemic metabolic improvements that occur
with CL-316,243 treatment, and may be targets for future
T2D treatments.
Conclusions
Overall, this study uses microarray and computational
analysis to demonstrate that FA oxidation genes are
significantly altered in the metabolic tissues of diabetic
and pre-diabetic MKR mice. In addition, it uncovers bio-
marker genes such as ACAA1 and HSD17b4 which
could be further probed in future studies of pre-diabetes
and T2D. Furthermore, it identifies novel changes that
occur upon treatment with CL-316,243, which not only
explain the lower free fatty acid levels in MKR mice after
treatment but also may provide targets for future therap-
ies for T2D.
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